Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lubiprostone for opioid-induced bowel dysfunction
2010-022991-29Phase 3Completed
- Sponsor
- Sucampo Pharmaceuticals
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced bowel dysfunction (OIBD) and functional gastrointestinal disorder (FGID) comparing Lubiprostone 48 mcg/day with Placebo (2 arms). Primary endpoint: Overall spontaneous bowel movement (SBM) response rate. Started Dec 2010; status: completed.
02
Drugs
cobiprostone
03
Conditions
opioid-induced bowel dysfunction (OIBD)functional gastrointestinal disorder (FGID)
Beyond the preview
Go deeper on 2010-022991-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022991-29.